Ray Furey
Executive Vice President, General Counsel, and Corporate Secretary
Replay available
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Q2 2026 earnings conference call, held 2026-08-04. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Raul Rodriguez
President and Chief Executive Officer
Dave Santos
Chief Commercial Officer
Dr. Alison Hannah
Chief Medical Officer
Dean Schorno
Chief Financial Officer
Joe Pangenius
Analyst, AC Wainwright
Amin Khan
Analyst, Jefferies
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Rigel Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.973 Greetings and welcome to the Rigel Pharmaceuticals Financial Conference call for the 00:00:03.973 -- 00:00:08.896 second quarter of 2026. At this time, all participants are on a listen-only mode. 00:00:08.896 -- 00:00:12.418 A brief question and answer session will follow the formal presentation. 00:00:12.418 -- 00:00:15.780 If anyone should require operator assistance during the conference, please press star 00:00:15.780 -- 00:00:20.543 zero on your telephone keypad. As a reminder, this conference is being recorded. 00:00:20.543 -- 00:00:24.966 It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice 00:00:24.966 -- 00:00:28.047 President, General Counsel, and Corporate Secretary. 00:00:28.047 -- 00:00:30.608 Thank you, Mr. Furey. 00:00:31.709 -- 00:00:36.972 Welcome to our second quarter of 2026 financial results and business update conference 00:00:36.972 -- 00:00:42.016 call. The financial press release for the second quarter of 2026 was issued earlier 00:00:42.016 -- 00:00:46.680 today and can be viewed along with the slides for this presentation in the news events 00:00:46.680 -- 00:00:51.263 section of our investor relations site on bridal.com. 00:00:51.263 -- 00:00:55.986 As a reminder, during today's call, we may make forward-looking statements regarding 00:00:55.986 -- 00:01:00.833 our financial outlook and our plans and timing for commercial regulatory product development 00:01:00.833 -- 00:01:03.276 and other business activities. 00:01:03.276 -- 00:01:08.581 These statements are subject to risks and uncertainties that may cause actual results 00:01:08.581 -- 00:01:14.456 to differ from those forecasted. Description of those risks can be found 00:01:14.456 -- 00:01:17.277 Thank you. Thank y...